Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 63, Topic 5
In Progress

Recovery, Rehabilitation, and Transition of Care Post-Sepsis

Lesson Progress
0% Complete
Recovery, Rehabilitation, and Transition of Care Post-Sepsis

Recovery, Rehabilitation, and Transition of Care Post-Sepsis

Objective Icon A clipboard with a checkmark, symbolizing a clinical plan.

Objective

Develop a plan to facilitate patient recovery, mitigate long-term complications, and ensure a safe transition of care.

1. Weaning and De-escalation of Life-Sustaining Therapies

Systematic reduction of vasopressors, ventilator support, and antibiotics as physiological stability returns is crucial to minimize iatrogenic harm and restore patient autonomy.

A. Vasopressor Weaning Protocol

  • Entry Criteria: MAP ≥ 65 mm Hg for at least 2 hours on norepinephrine ≤ 0.05 µg/kg/min; demonstrating improving lactate clearance (>10%/h) and adequate urine output (>0.5 mL/kg/h).
  • Tapering Algorithm: Reduce infusion by 10–20% every 30–60 minutes if MAP remains ≥ 65 mm Hg. Hold the taper or revert to the previous dose if MAP falls below 60 mm Hg or lactate begins to rise.
  • Transition: Once off intravenous support, assess for persistent orthostasis. If present, consider oral agents like midodrine to facilitate mobilization.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Vasopressor Weaning

Small, frequent reductions in vasopressor infusion rates allow for the recovery of endogenous catecholamine production and help prevent rebound hypotension, ensuring a smoother transition.

B. Mechanical Ventilation Liberation

  • Daily Spontaneous Awakening Trials (SAT): Pause sedation daily to assess neurologic function and readiness for weaning, aiming for a Richmond Agitation-Sedation Scale (RASS) score of −1 to +1.
  • Spontaneous Breathing Trials (SBT): If a patient passes the SAT, proceed to an SBT using a T-piece or minimal pressure support (≤ 7 cm H₂O) for 30–120 minutes with FiO₂ ≤ 40% and PEEP ≤ 5 cm H₂O.
  • Extubation Criteria: Successful SBT completion plus stable gas exchange (PaO₂/FiO₂ > 150), an effective cough to clear secretions, and an intact mental status.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Expediting Liberation

Combining daily SAT/SBT protocols with early mobilization and targeted inspiratory muscle training can significantly reduce the incidence of ICU-acquired weakness and shorten the duration of mechanical ventilation.

C. Antimicrobial De-escalation

  • Reassessment at 48–72 hours: Review culture data and clinical response. Narrow the antibiotic spectrum to target identified pathogens or discontinue therapy if a non-infectious cause is confirmed.
  • Typical Durations: Aim for 5–7 days for uncomplicated bacteremia or pneumonia. Extend to 10–14 days only if there is a deep-seated infection, incomplete source control, or profound immunosuppression.
  • Biomarker Guidance: A procalcitonin level < 0.25 ng/mL or a >80% drop from its peak value can support the safe discontinuation of antibiotics, particularly in respiratory infections.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Antimicrobial Stewardship

Prolonged or unnecessarily broad-spectrum antibiotic use drives antimicrobial resistance and increases the risk of side effects. Stop antibiotics promptly unless there is a clear, ongoing indication for their use.

2. Conversion to Enteral Medication Regimens

Transitioning from intravenous to oral or enteral therapy as soon as feasible preserves gut integrity, reduces the risk of central line-associated bloodstream infections (CLABSI), and is a key step in discharge planning.

A. GI Function Assessment

  • Assess for return of bowel function by checking for bowel sounds, performing a non-distended abdominal exam, and ensuring gastric residual volumes are < 500 mL.
  • The presence of hemodynamic stability on low-dose vasopressors (e.g., norepinephrine ≤ 0.1 µg/kg/min) is generally considered acceptable for initiating trophic enteral feeds.

B. Enteral Formulation Selection & Administration

Common Enteral Medication Conversions and Considerations
Drug Formulation Crushable? Feeding Interaction Administration Tip
Ciprofloxacin IR tablet Yes ↓ bioavailability with Ca/Mg Separate feeds by 2 h; flush tube well.
Phenytoin IR capsule Yes (open) Adsorption to tube material Hold feeds 1 hour before and after dose.
Metoprolol IR tablet Yes None significant Crush finely, dilute in water, flush before/after.
Levothyroxine IR tablet Yes Food delays absorption Administer on an empty stomach, 30-60 min before feeds.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Tube Patency

To prevent tube occlusion, flush feeding tubes with 15–30 mL of water before and after administering each medication. Never mix medications together in the same syringe.

3. Prevention and Management of Post-ICU Syndrome (PICS)

Early identification of at-risk patients and consistent implementation of bundle-based interventions are effective strategies to reduce the long-term cognitive, physical, and psychological impairments associated with critical illness.

A. High-Risk Patient Identifiers

  • Age > 65 years
  • ICU length of stay > 7 days
  • Duration of mechanical ventilation > 48 hours
  • Presence of delirium for > 2 days
  • High cumulative doses of sedatives, especially benzodiazepines

B. The ABCDEF Bundle

The ABCDEF bundle is a multidisciplinary, evidence-based approach to harmonizing ICU care practices to improve outcomes for critically ill patients.

ABCDEF Bundle Diagram A circular diagram illustrating the six components of the ABCDEF bundle for ICU care: A for Assess Pain, B for Both SAT/SBT, C for Choice of Sedation, D for Delirium, E for Early Mobility, and F for Family Engagement. ABCDEF Bundle A Assess, Prevent & Manage Pain B Both SAT & SBT C Choice of Analgesia & Sedation D Delirium: Assess, Prevent, Manage E Early Mobility & Exercise F Family Engagement & Empowerment
Figure 1: The ABCDEF Bundle. A patient-centered framework for organizing ICU care processes to improve survival, reduce delirium and coma, and decrease long-term consequences for patients and their families.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Bundle Impact

Consistent application of the ABCDEF bundle has been shown to shorten the duration of mechanical ventilation by approximately one day and reduce the duration of delirium by about 30%.

4. Medication Reconciliation and Discharge Planning

A structured, pharmacist-led process is essential to prevent medication errors, optimize patient adherence, and ensure a safe and effective handoff to the next level of care.

A. Reconciliation Workflow

  1. Collection: A best possible medication history (pre-admission list) is collected at ICU admission.
  2. Documentation: All in-ICU medication changes (initiations, discontinuations, dose adjustments) are documented daily.
  3. Reconciliation: A final, formal reconciliation is performed at discharge to resolve any discrepancies, omissions, or duplications between the pre-admission and current medication lists.

B. Patient and Caregiver Education

  • Provide clear, written medication schedules, pill organizers, and information on mobile app reminders.
  • Educate on “red flag” symptoms that warrant immediate contact with a healthcare provider, such as new weakness, altered cognition, or signs of infection.
  • Discuss the potential for PICS symptoms (anxiety, memory problems, fatigue) and normalize the experience.

C. Handoff Communication Tools

Utilize a standardized handoff template, such as SBAR, within the electronic health record to ensure all critical information is conveyed.

  • Situation: Patient is being discharged after recovery from septic shock.
  • Background: Summarize sepsis etiology, key interventions (e.g., vasopressors, ventilation), and hospital course.
  • Assessment: Current clinical status, key unresolved issues, and medication list.
  • Recommendation: Specific follow-up appointments, pending tests, and therapy goals.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Pharmacist-Led Reconciliation

Studies show that pharmacist-led medication reconciliation at hospital transitions can reduce medication discrepancies by approximately 66% and subsequent adverse drug events by up to 45%.

5. Long-Term Follow-Up and Rehabilitation Programs

Ongoing, multidisciplinary care is vital for addressing late-emerging sequelae of critical illness and tracking key recovery metrics over time.

A. Post-Critical Illness Clinics

Specialized clinics provide a structured environment for follow-up. They are typically scheduled 1–3 months post-discharge and staffed by a team including an intensivist, pharmacist, rehabilitation specialist, and psychologist.

B. Monitoring for Sequelae

  • Cognition: Screen with the Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE) at each visit.
  • Physical Function: Assess with objective measures like the 6-Minute Walk Test and handgrip dynamometry.
  • Emotional Health: Use validated screening tools such as the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.

C. Quality Improvement Metrics

Key metrics to track the success of a post-sepsis recovery program include the 30-day hospital readmission rate, the proportion of patients returning to baseline Activities of Daily Living (ADLs), and patient-reported quality of life (QoL) scores.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Improving Access to Care

For survivors with limited mobility or those in remote areas, telehealth-based follow-up can significantly improve access to specialized post-ICU care and reduce appointment no-show rates.

References

  1. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063–e1143.
  2. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809–818.
  3. Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led Medication Reconciliation Programmes at Hospital Transitions: A Systematic Review and Meta-analysis. J Clin Pharm Ther. 2016;41(2):128–144.
  4. Reignier J, Boisramé-Helms J, Brisard L, et al. Enteral versus Parenteral Early Nutrition in Ventilated Adults with Shock (NUTRIREA-2). Lancet. 2018;391(10116):133–143.
  5. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis. JAMA. 2010;304(16):1787–1794.